JAMA internal medicine

Nirmatrelvir-Ritonavir and Symptoms in Adults with Long COVID

Updated

Abstract

A 15-day course of nirmatrelvir-ritonavir did not show a significant benefit in reducing the severity of select symptoms in 155 participants with postacute sequelae of SARS-CoV-2 infection.

  • Participants had a median age of 43 years, with a majority being female (59%).
  • The study included adults with moderate to severe PASC symptoms lasting 3 months or longer.
  • No significant differences were observed in the severity of six core symptoms at 10 weeks between the treatment and placebo groups.
  • Patient Global Impression scores and changes in fatigue, dyspnea, cognitive function, and physical function measures did not differ significantly between groups.
  • Adverse event rates were similar across both treatment and placebo groups, with most events being of low grade.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Conflict of Interest Disclosures: Dr Geng reported grants from Pfizer during the conduct of the study; personal fees from UnitedHealth Group; and grants from the US National Institutes of Health (NIH), and the Agency for Healthcare Research and Quality (AHRQ) outside the submitted work. Dr Bonilla reported grants from Pfizer during the conduct of the study and consulting fees from Resverlogix outside the submitted work. Dr Hedlin reported financial support by Pfizer during the conduct of the study and grants from the NIH outside the submitted work. Dr Jacobson reported grants from the National Institute of Allergy and Infectious Diseases outside the submitted work. Dr Jagannathan reported grants from Pfizer for an industry-sponsored trial during the conduct of the study. Dr Subramanian reported grants from Moderna outside the submitted work. Dr Botzheim reported grants from Pfizer during the conduct of the study. Dr Desai reported grants from the NIH outside the submitted work. Dr Bhatt reported grants and honorarium from the NIH; grants from Emerson Collective, Stand Up 2 Cancer, Stanford University, and the Paul Allen Foundation; consulting and advisory board membership for Stylus Medicine, Caribou Biosciences, and BiomX outside the submitted work. Dr Shafer reported Speaking honorarium from Gilead, ViiV Healthcare, and advisory fees from GlaxoSmithKline outside the submitted work. Dr Miglis reported consulting/advisory fees from 2nd MD, Alight Health, Jazz Pharmaceuticals, and Pfizer; grants from Dysautonomia International, NIH, Embr Wave, Argenx; and royalty fees from Elsevier outside the submitted work. Dr Banerjee reported equity in Pfizer during the conduct of the study. Dr Utz reported funding including partial salary and financial support of laboratory during the conduct of the study. Dr Singh reported grants from Pfizer during the conduct of the study; grants from the NIH and AHRQ, advisory fees from Gilead and Regeneron for COVID-19 studies outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free